Stuart Weston
Affiliations: | Microbiology and Immunology | University of Maryland School of Medicine, Baltimore, MD, United States |
Google:
"Stuart Weston"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jassey A, Logue J, Weston S, et al. (2023) SIRT-1 is required for release of enveloped enteroviruses. Elife. 12 |
| Ardanuy J, Johnson R, Dillen C, et al. (2023) Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses. Mbio. e0158723 |
| Logue J, Johnson RM, Patel N, et al. (2023) Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants. Nature Communications. 14: 1130 |
| Lai J, Coleman KK, Tai SS, et al. (2022) Exhaled Breath Aerosol Shedding by Highly Transmissible Versus Prior SARS-CoV-2 Variants. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America |
| Logue J, Chakraborty AR, Johnson R, et al. (2022) PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. Communications Biology. 5: 808 |
| Davenport BJ, Catala A, Weston SM, et al. (2022) Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. Npj Vaccines. 7: 57 |
| DeGrace MM, Ghedin E, Frieman MB, et al. (2022) Defining the risk of SARS-CoV-2 variants on immune protection. Nature |
| Schultz DC, Johnson RM, Ayyanathan K, et al. (2022) Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature |
| Nanishi E, Borriello F, O'Meara TR, et al. (2022) An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine. 14: eabj5305 |
| Boras B, Jones RM, Anson BJ, et al. (2021) Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications. 12: 6055 |